Nasdaq:TGTX
TG THERAPEUTICS, INC.
TG Therapeutics is a promising biotech firm commercializing breakthrough therapies for severe lung diseases with rapid revenue scaling and achieved profitability.
Key Metrics
Investment Thesis
Bull Case
Investors should consider TGTX due to its explosive revenue growth trajectory and the achievement of net profitability, signaling a mature business model beyond early-stage biotech risks. The company holds significant cash reserves relative to its current liabilities, providing ample runway for further R&D or strategic acquisitions without immediate equity dilution. A specialized focus on underserved respiratory markets offers limited but high-value competition, potentially leading to sustained pricing power.
Bear Case
Caution is warranted given the volatility of revenue growth, which jumped from $233.7M in 2023 to $616.3M in 2025, raising concerns about customer concentration or unsustainable sales cycles. The negative operating cash flow despite net income highlights potential non-cash adjustments or aggressive accruals that may not reflect true economic performance. High levels of long-term debt and a substantial retained earnings deficit suggest historical financial instability that could resurface if market conditions deteriorate.
About TG THERAPEUTICS, INC.
TG Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for severe respiratory diseases, primarily targeting alpha-1 antitrypsin deficiency (AATD) and other lung conditions. The company serves the global healthcare market with its proprietary drug candidates, leveraging its robust pipeline to address unmet needs in pulmonology. With significant recent revenue growth and profitability, TGTX positions itself as a key player in the specialized biopharmaceutical sector.
Analysis
Management Discussion
Management has executed a remarkable turnaround, transforming the company into a profitable entity with revenue surging from $2.8M in 2022 to $616.3M in 2025. Despite negative operating cash flows of $24.8M and net changes in cash of -$100.7M, the company maintains a healthy balance sheet with $79.1M in cash and equivalents against $415.2M in total liabilities. The shift from a massive retained earnings deficit to a positive net profit indicates successful commercialization efforts.
Industry Overview
The global respiratory disease treatment market is highly competitive, dominated by large pharmaceutical firms, yet remains fragmented in niche areas like alpha-1 antitrypsin deficiency. Biotechnology companies are increasingly focusing on orphan drugs and specialized therapies to capture regulatory incentives and address gaps left by conventional treatments. Success in this sector requires robust clinical data, strategic partnerships, and the ability to navigate complex reimbursement landscapes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.8M | $233.7M | $329.0M | $616.3M |
| Cost of Revenue | $0 | $14.1M | $38.5M | $100.7M |
| Gross Profit | $2.8M | $219.5M | $290.5M | $515.6M |
| Operating Expenses | $195.6M | $198.9M | $248.6M | $392.2M |
| Operating Income | $-192.8M | $20.6M | $41.9M | $123.3M |
| R&D | $125.4M | $76.2M | $94.3M | $160.2M |
| G&A | $70.0M | $122.7M | $154.3M | $232.0M |
| Stock-Based Comp | $19.2M | $37.9M | $42.5M | $64.7M |
| D&A | — | $211.0K | $68.0K | $59.0K |
| Depreciation | $303.0K | — | — | — |
| Amortization | $212.0K | — | — | — |
| Other OpEx | $265.0K | $0 | $0 | $0 |
| Non-Operating Income | $-5.5M | $-7.6M | $-16.3M | $-15.9M |
| Interest Expense | $10.2M | $12.6M | — | — |
| Pre-Tax Income | $-198.3M | $13.1M | $25.6M | $107.4M |
| Income Tax | $0 | $390.0K | $2.2M | $-339.8M |
| Continuing Ops | $-198.3M | $12.7M | $23.4M | $447.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-198.3M | $12.7M | $23.4M | $447.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-198.3M | $12.7M | $23.4M | $447.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $168.3M | $317.9M | $566.4M | $630.8M |
| Cash & Equivalents | $102.3M | $92.9M | $179.9M | $79.1M |
| Marketable Securities | $59.4M | $124.6M | $131.1M | $62.8M |
| Accounts Receivable | — | $51.1M | $129.2M | $305.6M |
| Inventory | — | $39.8M | $110.5M | $125.6M |
| Other Current Assets | $6.6M | $9.5M | $15.7M | $57.6M |
| Long-Term Assets | $25.3M | $11.6M | $11.3M | $432.5M |
| PP&E (Net) | $307.0K | $95.0K | — | — |
| Goodwill | $799.0K | $799.0K | — | — |
| Operating Leases | $8.9M | $8.1M | $7.2M | $6.3M |
| LT Investments | $12.4M | $0 | $808.0K | $59.1M |
| Other LT Assets | $2.9M | $2.7M | $3.4M | $367.1M |
| Total Assets | $193.6M | $329.6M | $577.7M | $1.06B |
| Current Liabilities | $53.2M | $53.7M | $90.7M | $153.8M |
| Current Debt | $0 | — | — | — |
| Current Leases | $1.6M | $1.4M | $1.2M | $1.0M |
| Other Current Liab | $51.6M | $52.3M | $89.5M | $152.7M |
| Long-Term Liabilities | $81.8M | $115.4M | $264.6M | $261.5M |
| Long-Term Debt | $71.1M | $100.1M | $244.4M | $245.6M |
| LT Operating Leases | $10.3M | $9.2M | $8.1M | $7.0M |
| Other LT Liab | $305.0K | $6.0M | $12.1M | $8.8M |
| Total Liabilities | $135.0M | $169.1M | $355.3M | $415.2M |
| Shareholders' Equity | $58.6M | $160.5M | $222.4M | $648.0M |
| Paid-In Capital | $1.59B | $1.67B | $1.76B | $1.83B |
| Retained Earnings | $-1.53B | $-1.51B | $-1.53B | $-1.08B |
| Treasury Stock | $200.0K | $200.0K | $9.0M | $100.2M |
| Total L&E | $193.6M | $329.6M | $577.7M | $1.06B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-198.3M | $12.7M | $23.4M | $447.2M |
| Non-Cash Adjustments | $43.0M | $-141.2M | $-257.1M | $-782.1M |
| Working Capital Changes | $-20.8M | $97.1M | $193.2M | $310.1M |
| Cash from Operations | $-176.2M | $-31.4M | $-40.5M | $-24.8M |
| Capital Expenditures | $14.0K | $0 | $45.0K | $214.0K |
| Cash from Investing | $-20.0M | $-50.7M | $-1.0M | $13.8M |
| Cash from Financing | $-391.0K | $72.7M | $128.5M | $-89.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-196.6M | $-9.4M | $87.0M | $-100.7M |
| Beginning Cash | $300.2M | $103.6M | $94.2M | $181.2M |
| Ending Cash | $103.6M | $94.2M | $181.2M | $80.5M |
Frequently Asked Questions
How does TG THERAPEUTICS, INC. make money?
The company's financials indicate a primary revenue stream from its flagship drug candidate, likely TG-101, which generates substantial gross profit. Secondary segments include ongoing research and development costs allocated to clinical trials for additional indications, as well as potential licensing or collaboration agreements reflected in the operating expenses structure.
What are the main risks for TGTX?
Rapid revenue growth over the last three years suggests potential market saturation or aggressive sales tactics that could lead to future margin compression if not managed carefully. The company faces inherent biotech risks including clinical trial failures, regulatory hurdles from the FDA, and competition from larger pharmaceutical players entering the respiratory disease space. Significant investment in research and development remains a drain on resources, though currently offset by profits, creating dependency on continued cash flow generation.
What is TGTX's competitive advantage?
TGTX possesses a unique intellectual property portfolio focused on alpha-1 antitrypsin deficiency, providing a first-mover advantage in this niche therapeutic area. The company demonstrates strong operational efficiency with high gross margins relative to its revenue base and has successfully transitioned to profitability while maintaining substantial cash reserves. Its ability to scale production and manage working capital effectively allows it to fund expansion without immediate dilution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.